Patents by Inventor Rainer BOXHAMMER

Rainer BOXHAMMER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240009196
    Abstract: The present disclsoure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: February 1, 2023
    Publication date: January 11, 2024
    Inventors: Jan ENDELL, Rainer BOXHAMMER, Mark WINDERLICH
  • Publication number: 20220283166
    Abstract: The present disclosure is directed to identifying characteristics and biomarkers in patients that benefit from treatment with an anti-CD19 antibody.
    Type: Application
    Filed: May 25, 2022
    Publication date: September 8, 2022
    Inventors: Jan ENDELL, Mark WINDERLICH, Rainer BOXHAMMER
  • Publication number: 20220144965
    Abstract: The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of anti-PLA2R positive membranous glomerulonephropathy.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Inventors: Daniel KLUNKER, Rainer BOXHAMMER, Stefan HÄRTLE, Stefan STEIDL, Tiantom JARUTAT
  • Publication number: 20220088197
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: December 8, 2021
    Publication date: March 24, 2022
    Inventors: Jan ENDELL, Mark WINDERLICH, Rainer BOXHAMMER
  • Publication number: 20220047632
    Abstract: Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: September 5, 2019
    Publication date: February 17, 2022
    Inventors: Jung Hyun HER, Mi Young JUNG, Su Hyun GWON, Ho Yong LIM, Sung Yoo CHO, Sung Yong WON, Yu Kyeong HWANG, Jan ENDELL, Rainer BOXHAMMER
  • Publication number: 20200206228
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: March 2, 2020
    Publication date: July 2, 2020
    Inventors: Jan ENDELL, Rainer BOXHAMMER, Mark WINDERLICH
  • Publication number: 20180022823
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: August 7, 2017
    Publication date: January 25, 2018
    Inventors: LISA ROJKJAER, RAINER BOXHAMMER, JAN ENDELL, MARK WINDERLICH, CHRISTOFER SAMUELSSON
  • Publication number: 20110311553
    Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 22, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias LITZENBURGER, Sandra MILLER, Catrin PRACHT, Rainer BOXHAMMER, Jeanne MAGRAM, Patricia GIBLIN, Daniel RAJOTTE
  • Publication number: 20100119506
    Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
    Type: Application
    Filed: July 30, 2009
    Publication date: May 13, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias LITZENBURGER, Sandra MILLER, Catrin PRACHT, Rainer BOXHAMMER, Jeanne MAGRAM, Patricia GIBLIN, Daniel RAJOTTE